Internet broadcasting sensation Andrew Zarian, founder of the Guys From Queens Network (GFQ), joins Spencer Kobren in studio to take his first dose of the controversial hair loss drug Propecia live on the air.
Alopecia Areata affects approximately two percent of the world’s population, which includes more than 6.5 million American men, women and children. According to The American Hair Loss Association, Alopecia Areata (AA) is the third most common form of hair loss dermatologists see in their practices, and is considered one of the most emotionally devastating of all dermatological diseases.
Until now, treatments for Alopecia Areata, Totalis and Universalis have been mildly effective at best.
Watch Spencer Kobren’s in-depth interview with Assistant Professor of Dermatology at Yale University School of Medicine, Dr. Brett King, as he discusses, how with the help of Dr. Angela Christiano’s groundbreaking research, he reversed the hair loss process in a young man who suffered with AA for most of his life.
Low level laser light therapy (LLLT) as an effective treatment for hair loss has been the topic of some pretty heated debates on TBT over the years. While LLLT is still not recognized by The American Hair Loss Association as an effective treatment for Androgenetic Alopecia, many respected experts in the field believe that certain devices on the market can actually help hair loss sufferers.
Clinical studies have shown that LLLT has been able to stimulate hair growth in mice with chemotherapy-induced alopecia, however the data for human hair growth might be considered by some as being more subjective. With that said, there does seem to be growing anecdotal evidence that these laser devices might just be doing something.
Check out Spencer Kobren and Alan J. Bauman, M.D., discussing the reality of LLLT therapy for hair loss and Dr. B’s recent appearance on The Doctors.
"Spencer Kobren's nationally syndicated show "The Bald Truth" has a dedicated listenership that would have Rush Limbaugh pulling his hair out in envy." --Pittsburgh Tribune-Review.